Rocket Lab Usa Inc SEC Filings

Rocket Lab Corporation (NASDAQ: RKLB) has released Definitive Additional Proxy Materials (DEFA14A) ahead of its virtual 2025 Annual Meeting scheduled for August 27, 2025 at 1:30 p.m. PT. Shareholders of record as of the meeting date are asked to vote on four proposals:

• Election of three Class I directors – Jon Olson, Merline Saintil and Alex Slusky – for terms expiring in 2028.
• Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025.
• Advisory (non-binding) vote on named-executive-officer compensation (Say-on-Pay).
• Amendment to the Amended & Restated Certificate of Incorporation of subsidiary Rocket Lab USA, Inc. to remove the recently added pass-through voting provision that currently requires separate approvals by both Rocket Lab Corporation and its shareholders before specified subsidiary actions can occur.

The Board of Directors unanimously recommends “FOR” all items. Voting can be completed online at www.ProxyVote.com until 11:59 p.m. ET on August 26, 2025, or live during the virtual meeting at www.virtualshareholdermeeting.com/RKLB2025. No filing fee was required for this submission.

Insmed, Inc. (INSM) – Form 144 notice of proposed sale

The filing discloses that Michael A. Smith intends to sell 748 shares of Insmed common stock through Merrill Lynch on or about 11 July 2025. The shares carry an aggregate market value of $72,114, implying a reference price of roughly $96 per share. Insmed has 182,138,923 shares outstanding, so the planned sale represents only 0.0004 % of the float.

The form also lists insider transactions over the preceding three months: Smith sold 34,470 shares between 14 May 2025 and 5 June 2025 for gross proceeds of $2.4 million. Even these cumulative sales equal just 0.019 % of shares outstanding. All sales were made under Rule 144, which governs the resale of restricted or control securities.

No financing, earnings, or operational data accompany the filing; the document’s sole purpose is to give advance notice of this modest insider disposition and to certify that the seller is unaware of undisclosed material adverse information.

Rocket Lab Corporation (RKLB) – Form 4 insider transaction

On 2 July 2025, Khosla Ventures V, L.P. ("KV V") and its affiliated entities filed a Form 4 reporting an internal, non-cash reallocation of Rocket Lab common shares. KV V distributed 2,000,000 shares pro-rata to its limited and general partners under transaction code “J” (other, no consideration). The filing confirms:

• After the distribution, KV V’s indirect ownership stands at 19,323,617 shares.
• 747,699 shares of the distributed amount were received by Khosla Ventures Associates V, LLC ("KVA V"). KVA V subsequently passed all of those shares to its members.
• VK Services, LLC, an entity controlled by Vinod Khosla, received 487,789 shares and is now the record owner of 30,146,841 shares.
• No cash changed hands; the stated price is $0.00.
• The reporting persons—KV V, KVA V, VK Services, and Vinod Khosla—each continue to be classified as 10% beneficial owners of Rocket Lab.

The transaction reflects an internal capital account distribution rather than an open-market sale or purchase, and therefore does not directly alter Rocket Lab’s outstanding share count or bring immediate cash proceeds to any party. All parties expressly disclaim beneficial ownership beyond their pecuniary interest.

Additional note: On 23 May 2025, Rocket Lab Corporation became the parent holding company of Rocket Lab USA, Inc. via merger; this Form 4 relates to the parent entity.

Codexis, Inc. (CDXS) received a Form 4 filing from Opaleye Management Inc., a 10% beneficial owner, detailing an open-market purchase completed on 27 June 2025.

• Transaction: 100,000 shares of Codexis common stock were purchased (Code P) at an average price of $2.39 per share.
• Post-transaction holdings: Opaleye now reports 12,350,000 shares held indirectly through Opaleye, L.P. and an additional 250,000 shares in a separately managed account, bringing total reported beneficial ownership to 12.6 million shares.
• Ownership form: All shares are reported as indirect (Form I); the investment manager disclaims beneficial ownership beyond its pecuniary interest.
• Reporting party status: Opaleye is classified as a 10% owner; no board or executive role is indicated.

The filing signals incremental insider accumulation by a large shareholder. While the 100 k-share purchase is modest relative to the 12.35 million-share position, fresh buying can be interpreted by investors as a vote of confidence in Codexis at current price levels. No derivative transactions, sales or options were disclosed in this filing.

Rocket Lab Corp director Merline Saintil executed two planned sales transactions on June 24, 2025, disposing of a total of 6,353 shares of common stock through a pre-established Rule 10b5-1 trading plan from March 20, 2025.

Transaction details:

• First sale: 4,053 shares at weighted average price of $33.1473 (range: $32.51-$33.50)
• Second sale: 2,300 shares at weighted average price of $33.7848 (range: $33.51-$34.13)
• Remaining direct ownership: 419,569 shares

The transactions were executed according to a predetermined trading plan, which provides an affirmative defense against insider trading allegations. The sales were reported within the required two-business-day filing deadline.

Rocket Lab Corp (RKLB) director Merline Saintil executed planned stock sales on June 20, 2025, through a pre-established Rule 10b5-1 trading plan from March 20, 2025. The transactions involved:

• Sale of 1,700 shares at a weighted average price of $28.75 (range: $28.03-$29.01)
• Sale of 4,653 shares at a weighted average price of $29.65 (range: $29.08-$30.04)

Following these transactions, Saintil's direct ownership decreased from 432,275 to 425,922 shares. The sales were executed automatically according to the trading plan, demonstrating structured portfolio management by the insider. The Form 4 was signed by Arjun Kampani as Attorney-in-Fact for Saintil on June 23, 2025.

Rocket Lab Corporation (NASDAQ: RKLB) has filed a Form 144 notice indicating a proposed sale of securities by an insider. The filing details plans to sell 12,706 shares of common stock with an aggregate market value of $353,862.10, representing a small portion of the company's 461,432,393 outstanding shares.

Key transaction details:

• Shares were acquired through Restricted Stock Units on June 12, 2025
• Sale to be executed through Morgan Stanley Smith Barney LLC
• Approximate sale date: June 20, 2025
• Average price per share: approximately $27.85

The filing indicates no other sales by the insider in the past three months. The seller has certified compliance with Rule 10b5-1 and confirms no knowledge of undisclosed material adverse information regarding Rocket Lab's operations.